NIK as a Druggable Mediator of Tissue Injury

Abstract

NF-κB-inducing kinase (NIK, MAP3K14) is best known as the apical kinase that triggers non-canonical NF-κB activation and by its role in the immune system. Recent data indicate a role for NIK expressed by non-lymphoid cells in cancer, kidney disease, liver injury, glucose homeostasis, osteosarcopenia, vascular calcification, hematopoiesis, and endothelial function. The spectrum of NIK-associated disease now ranges from immunodeficiency (when NIK is defective) to autoimmunity, cancer, sterile inflammation, fibrosis, and metabolic disease when NIK is overactive. The development of novel small-molecule NIK inhibitors has paved the way to test NIK targeting to treat disease in vivo, and may eventually lead to NIK targeting in the clinic. In addition, NIK activators are being explored for specific conditions such as myeloid leukemia.

Keywords: MAP3K14; NIK; TWEAK; acute kidney injury; apoptosis; autoimmunity; cell death; chronic kidney disease; cirrhosis; diabetes; epigenetic; esteatohepatitis; hepatitis; inflammation; mantle lymphoma; myeloid leukemia; osteoporosis; sarcopenia; verteporfin.